Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
Over the last 12 months, insiders at HCW Biologics Inc. have bought $0 and sold $0 worth of HCW Biologics Inc. stock.
On average, over the past 5 years, insiders at HCW Biologics Inc. have bought $2.97M and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,800 shares for transaction amount of $3,741 was made by Wong Hing C (Chief Executive Officer) on 2023‑09‑14.
2023-09-14 | Wong Hing C | Chief Executive Officer | 1,800 0.0049% | $2.08 | $3,741 | -46.48% | ||
2023-09-14 | Winer Gary M | director | 1,041 0.0028% | $2.05 | $2,139 | -46.48% | ||
2023-09-13 | Byam Rebecca | Chief Financial Officer | 5,000 0.0144% | $2.10 | $10,490 | -43.32% | ||
2023-09-13 | Winer Gary M | director | 546 0.0015% | $2.05 | $1,117 | -43.32% | ||
2023-09-12 | Byam Rebecca | Chief Financial Officer | 5,000 0.0143% | $2.09 | $10,442 | -43.35% | ||
2023-09-12 | Winer Gary M | director | 500 0.0014% | $2.05 | $1,025 | -43.35% | ||
2023-09-11 | Byam Rebecca | Chief Financial Officer | 5,000 0.0145% | $2.05 | $10,273 | -41.62% | ||
2023-09-11 | Winer Gary M | director | 99 0.0003% | $2.05 | $203 | -41.62% | ||
2023-09-08 | Byam Rebecca | Chief Financial Officer | 5,000 0.0137% | $2.02 | $10,111 | -43.90% | ||
2023-09-08 | Winer Gary M | director | 1 <0.0001% | $1.90 | $2 | -43.90% | ||
2023-09-07 | Byam Rebecca | Chief Financial Officer | 5,000 0.0139% | $1.95 | $9,742 | -41.03% | ||
2023-09-07 | Winer Gary M | director | 63 0.0002% | $1.95 | $123 | -41.03% | ||
2023-09-06 | Byam Rebecca | Chief Financial Officer | 5,000 0.0144% | $1.95 | $9,749 | -39.15% | ||
2023-09-05 | Winer Gary M | director | 400 0.0011% | $1.75 | $700 | -41.03% | ||
2023-06-09 | Byam Rebecca | Chief Financial Officer | 20,000 0.057% | $2.06 | $41,286 | -20.79% | ||
2023-06-08 | Byam Rebecca | Chief Financial Officer | 4,696 0.0135% | $2.21 | $10,388 | -25.58% | ||
2023-06-08 | Flowers Lee | SVP of Business Development | 10,000 0.028% | $2.16 | $21,574 | -25.58% | ||
2023-06-07 | Byam Rebecca | Chief Financial Officer | 20,000 0.0542% | $2.03 | $40,632 | -23.37% | ||
2023-06-06 | Byam Rebecca | Chief Financial Officer | 19,062 0.0524% | $1.82 | $34,779 | -13.51% | ||
2023-06-05 | Byam Rebecca | Chief Financial Officer | 20,000 0.054% | $1.67 | $33,344 | -6.98% |
Wong Hing C | Chief Executive Officer | 15314868 34.3807% | $5.21M | 14 | 0 | <0.0001% |
Byam Rebecca | Chief Financial Officer | 573946 1.2885% | $195,141.64 | 22 | 0 | <0.0001% |
GARRETT SCOTT T | director | 125000 0.2806% | $42,500.00 | 1 | 0 | <0.0001% |
Flowers Lee | SVP of Business Development | 111308 0.2499% | $37,844.72 | 5 | 0 | <0.0001% |
Rhode Peter | See Remarks | 46785 0.105% | $15,906.90 | 1 | 0 | <0.0001% |
Jiao Jin-an | VP of Development | 30571 0.0686% | $10,394.14 | 1 | 0 | <0.0001% |
Winer Gary M | director | 17000 0.0382% | $5,780.00 | 11 | 0 | <0.0001% |
Greene Rick S. | 8411 0.0189% | $2,859.74 | 2 | 0 | <0.0001% |
HCW Biologics Inc. (HCWB) | $8,900,811 | 57 | -24.79% | $15.15M |
$85,897,100 | 36 | 2.47% | $17.01M | |
$217,684 | 34 | 1.61% | $17.89M | |
$4,368,362 | 28 | -22.35% | $14.54M | |
$550,893 | 22 | -22.12% | $15M | |
$555,628 | 21 | 43.52% | $17.92M | |
$206,127 | 21 | -29.00% | $16.71M | |
$2,553,853 | 17 | 16.69% | $15.38M | |
$37,194,483 | 17 | -51.30% | $15.85M | |
$122,973 | 15 | -26.96% | $14.53M | |
$389,864 | 11 | 12.52% | $15.03M | |
$38,247,728 | 10 | -10.97% | $13.84M | |
$36,538,405 | 10 | -21.99% | $14.11M | |
$70,584,874 | 10 | 3.97% | $15.33M | |
$189,648 | 9 | -52.20% | $14.86M | |
$2,060,158 | 5 | -21.35% | $16.73M | |
$45,953 | 2 | -2.16% | $17.7M | |
$31,190 | 2 | -14.18% | $14.74M | |
$245,940 | 2 | 31.12% | $14.24M |
Increased Positions | 4 | +16.67% | 2M | +180.17% |
Decreased Positions | 8 | -33.33% | 118,637 | -10.24% |
New Positions | 4 | New | 2M | New |
Sold Out Positions | 2 | Sold Out | 51,328 | Sold Out |
Total Postitions | 20 | -16.67% | 3M | +169.93% |
Armistice Capital, Llc | $769.00 | 4.5% | 2.02M | +2M | New | 2024-12-31 |
Avantax Planning Partners, Inc. | $106.00 | 0.62% | 279,541 | 0 | 0% | 2024-12-31 |
Geode Capital Management, Llc | $69.00 | 0.4% | 181,957 | -1,302 | -0.71% | 2024-12-31 |
Hightower Advisors, Llc | $69.00 | 0.4% | 180,810 | 0 | 0% | 2024-12-31 |
Cresset Asset Management, Llc | $50.00 | 0.29% | 131,990 | 0 | 0% | 2024-12-31 |
Pullen Investment Management, Llc | $29.00 | 0.17% | 75,116 | 0 | 0% | 2024-12-31 |
Blackrock, Inc. | $16.00 | 0.1% | 42,989 | -1,359 | -3.06% | 2024-12-31 |
Vanguard Group Inc | $14.00 | 0.08% | 37,677 | 0 | 0% | 2024-12-31 |
Bridgeway Capital Management, Llc | $13.00 | 0.08% | 34,700 | -50,000 | -59.03% | 2024-12-31 |
Xtx Topco Ltd | $13.00 | 0.08% | 33,999 | +33,999 | New | 2024-12-31 |